Showing 1521-1530 of 1690 results for "".
- Imaavy Outperforms Other FcRn Blockers in Sustained gMG Symptom Controlhttps://practicalneurology.com/news/imaavy-outperforms-other-fcrn-blockers-in-sustained-gmg-symptom-control/2475453/Results of an indirect treatment comparison (ITC) demonstrated that Imaavy (nipocalimab-aahu; Johnson & Johnson, New Brunswick, NJ) treatment was associated with consistent and sustained improvement in generalized myasthenia gravis (gMG) symptoms in individuals aged ≥12 years with anti-acetyl
- Skin Biopsy Detects Synuclein Pathology in 75% of Those with Idiopathic REM Sleep Behavior Disorderhttps://practicalneurology.com/news/skin-biopsy-detects-synuclein-pathology-in-75-of-those-with-idiopathic-rem-sleep-behavior-disorder/2475314/According to study results presented at the 2025 Annual Meeting of the Associated Professional Sleep Societies (APSS), 75% of people with idiopathic rapid eye movement (REM) sleep behavior disorder (iRBD) and no evidence of other neurodegenerative disease tested positive for cutaneous phosphoryla
- Novel Multi-Modal Screening Method for Classification of Narcolepsy Type 1 is Highly Specific and Sensitivehttps://practicalneurology.com/news/novel-multi-modal-screening-method-for-classification-of-narcolepsy-type-1-is-highly-specific-and-sensitive/2475086/Study results presented at the 2025 Annual Meeting of the Associated Professional Sleep Societies (APSS) demonstrated the specificity and sensitivity of a large-scale screening model for the classification of narcolepsy type 1 (NT1) which integrates polygenic risk scores (PRS), human leukocyte an
- Sunosi Significantly Reduced Excessive Daytime Sleepiness and Obstructive Sleep Apnea Symptoms in Real-World Studyhttps://practicalneurology.com/news/sunosi-significantly-reduced-excessive-daytime-sleepiness-and-obstructive-sleep-apnea-symptoms-in-real-world-study/2475070/The results of a real-world analysis presented at the 2025 Annual Meeting of the Associated Professional Sleep Societies (APSS) show that Sunosi (solriamfetol; Axsome Therapeutics, New York, NY) significantly reduced symptoms of excessive daytime sleepiness (EDS) in individuals with obstructive s
- Gene Therapy for Angelman Syndrome Cleared by FDA for First-in-Human Trialhttps://practicalneurology.com/news/gene-therapy-for-angelman-syndrome-cleared-by-fda-for-first-in-human-trial/2474638/MavriX Bio announced that it has received Food and Drug Administration (FDA) clearance for its Investigational New Drug (IND) application for MVX-220 (MavriX Bio, Middleton, MA), an adeno-associated virus (AAV) gene therapy for Angelman syndrome. MVX-220 is intended to restore neuronal UBE3A gene
- Study Results Support Rapid Blood Pressure Reduction After Spontaneous Intracerebral Hemorrhagehttps://practicalneurology.com/news/results-of-a-secondary-analysis-support-intensive-blood-pressure-reduction-to-140-mmhg-after-spontaneous-intracerebral-hemorrhage/2474074/Findings from a secondary analysis of data from the phase 3 ATACH-II clinical trial (NCT01176565) suggest that intensive systolic blood pressure (BP) reduction to below 140 mmHg within 90 minutes of randomization is associated with decreased risk of hematoma expansion (HE) for people with spontan
- Substantially Higher Mortality Risk Demonstrated for Children and Adolescents with Severe Epilepsy and Sleep Apneahttps://practicalneurology.com/news/substantially-higher-mortality-risk-demonstrated-for-children-and-adolescents-with-severe-epilepsy-and-sleep-apnea/2474009/Study results presented at the American Academy of Neurology (AAN) 2025 Annual Meeting demonstrate that central sleep apnea (CSA) and other sleep apnea, including obstructive sleep apnea (OSA), are associated with an increased risk of mortality in children and adolescents aged 1 to 17 years with
- Data Regarding Novel CD40 Ligand Inhibitor as Potential Treatment for Individuals with Relapsing MS Presented at AAN 2025https://practicalneurology.com/news/data-regarding-novel-cd40-ligand-inhibitor-as-potential-treatment-for-individuals-with-relapsing-ms-presented-at-aan-2025/2474004/Results from an open-label extension (OLE) of a phase 2 clinical trial (NCT04879628) for frexalimab (Sanofi; Bridgewater, NJ), an investigational CD40 ligand inhibitor not associated with lymphocyte depletion being studied as a potential treatment for people with relapsing multiple sclerosis, wer
- Norepinephrine Reuptake Inhibitor Treatment Significantly Reduced Cataplexy Attacks in People with Narcolepsy Type 1https://practicalneurology.com/news/nri-therapy-significantly-reduced-cataplexy-attacks-in-people-with-narcolepsy-type-1/2473965/Treatment with AXS-12 (reboxetine; Axsome, New York, NY), a highly selective norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator, was associated with significant reductions in cataplexy attacks in people with narcolepsy type 1 (NT1), according to results from the phase 3 SYMPH
- Stem Cell Therapy Reduced Brain Atrophy in People with Mild Alzheimer Diseasehttps://practicalneurology.com/news/stem-cell-therapy-reduced-brain-atrophy-in-people-with-mild-alzheimer-disease/2473818/The intravenous (IV) treatment of people with mild Alzheimer disease (AD) using Lomecel-B (laromestrocel; Longeveron, Miami, FL), a bone-marrow–derived allogeneic mesenchymal stem cell (MSC), was associated with reduced atrophy of the whole brain and hippocampus compared with placebo. These